ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

ClinicalTrials.gov ID: NCT04400331

Public ClinicalTrials.gov record NCT04400331. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 4:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Study identification

NCT ID
NCT04400331
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
Neurocrine Biosciences
Industry
Enrollment
154 participants

Conditions and interventions

Interventions

  • Valbenazine Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 75 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 17, 2020
Primary completion
Feb 28, 2026
Completion
Feb 28, 2026
Last update posted
Dec 23, 2024

2020 – 2026

United States locations

U.S. sites
31
U.S. states
24
U.S. cities
30
Facility City State ZIP Site status
Neurocrine Clinical Site Birmingham Alabama 35294
Neurocrine Clinical Site Little Rock Arkansas 72205
Neurocrine Clinical Site La Jolla California 92037
Neurocrine Clinical Site Aurora Colorado 80045
Neurocrine Clinical Site Washington D.C. District of Columbia 20007
Neurocrine Clinical Site Boca Raton Florida 33486
Neurocrine Clinical Site Gainesville Florida 32608
Neurocrine Clinical Site Atlanta Georgia 30329
Neurocrine Clinical Site Chicago Illinois 60611
Neurocrine Clinical Site Chicago Illinois 60612
Neurocrine Clinical Site Indianapolis Indiana 46202
Neurocrine Clinical Site Iowa City Iowa 52242
Neurocrine Clinical Site Wichita Kansas 67226
Neurocrine Clinical Site Louisville Kentucky 40202
Neurocrine Clinical Site New Orleans Louisiana 70121
Neurocrine Clinical Site Boston Massachusetts 02215
Neurocrine Clinical Site Charlestown Massachusetts 02129
Neurocrine Clinical Site Ann Arbor Michigan 48105
Neurocrine Clinical Site Omaha Nebraska 68105
Neurocrine Clinical Site Rochester New York 14618
Neurocrine Clinical Site Williamsville New York 14221
Neurocrine Clinical Site Durham North Carolina 27705
Neurocrine Clinical Site Columbus Ohio 43221
Neurocrine Clinical Site Toledo Ohio 43614
Neurocrine Clinical Site Pittsburgh Pennsylvania 15213
Neurocrine Clinical Site Charleston South Carolina 29425
Neurocrine Clinical Site Columbia South Carolina 29203
Neurocrine Clinical Site Greenville South Carolina 29615
Neurocrine Clinical Site Nashville Tennessee 37212
Neurocrine Clinical Site Houston Texas 77054
Neurocrine Clinical Site Burlington Vermont 05401

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 3 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT04400331, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 23, 2024 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04400331 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →